Update on mucous membrane pemphigoid: a heterogeneous immune-mediated subepithelial blistering entity
- PMID: 10442946
- DOI: 10.1016/s1079-2104(99)70194-0
Update on mucous membrane pemphigoid: a heterogeneous immune-mediated subepithelial blistering entity
Abstract
Most oral involvement in the skin diseases (dermatoses) is related to mucous membrane pemphigoid or lichen planus. Mucous membrane pemphigoid was the subject of a European Symposium held in Turin, Italy, in June 1997. This review is based on that symposium. Mucous membrane pemphigoid is a subepithelial vesiculobullous disorder mainly of late middle age; it has a slight predilection for women. Whereas mucous membrane pemphigoid was formerly considered a single entity, it is now quite evident that a number of subepithelial vesiculobullous disorders may produce similar clinical pictures and also that a range of variants of mucous membrane pemphigoid exists, with antibodies directed against various hemidesmosomal components or components of the epithelial basement membrane. The term immune-mediated subepithelial blistering diseases has therefore been used. Diagnosis and management of immune-mediated subepithelial blistering diseases on clinical grounds alone are impossible; a full history, general and oral examinations, and biopsy with immunostaining are now invariably required, sometimes supplemented with other investigations. Most patients with mucous membrane pemphigoid affecting the mouth manifest desquamative gingivitis, a fairly common complaint typically seen in women who are middle-aged or older. Oral vesicles and erosions may also occur, and there can be a positive Nikolsky sign. Some patients have lesions of other stratified squamous epithelia, presenting as conjunctival, nasal, oesophageal, laryngeal, vulval, penile, or anal involvement. Apart from improving oral hygiene, immunomodulatory-in particular, immunosuppressive-therapy is typically required to control oral lesions in mucous membrane pemphigoid. No single treatment regimen reliably controls all these disorders.
Similar articles
-
Oral mucosal diseases: mucous membrane pemphigoid.Br J Oral Maxillofac Surg. 2008 Jul;46(5):358-66. doi: 10.1016/j.bjoms.2007.07.200. Epub 2007 Sep 4. Br J Oral Maxillofac Surg. 2008. PMID: 17804127 Review.
-
Mucosal disease series. Number III. Mucous membrane pemphigoid.Oral Dis. 2005 Jul;11(4):197-218. doi: 10.1111/j.1601-0825.2005.01140.x. Oral Dis. 2005. PMID: 15984952 Review.
-
Childhood oral mucous membrane pemphigoid presenting as desquamative gingivitis in a 4-year-old girl.Acta Derm Venereol. 2006;86(4):351-4. doi: 10.2340/00015555-0083. Acta Derm Venereol. 2006. PMID: 16874424
-
Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specificity of autoantibodies.Arch Dermatol. 1993 Apr;129(4):448-55. doi: 10.1001/archderm.129.4.448. Arch Dermatol. 1993. PMID: 7682049
-
Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid).Clin Dermatol. 2012 Jan-Feb;30(1):34-7. doi: 10.1016/j.clindermatol.2011.03.007. Clin Dermatol. 2012. PMID: 22137224 Review.
Cited by
-
The Association Between Oral Health and Skin Disease.J Clin Aesthet Dermatol. 2020 Jun;13(6):48-53. Epub 2020 Jun 1. J Clin Aesthet Dermatol. 2020. PMID: 32884621 Free PMC article.
-
Desquamative gingivitis - A clinical sign in mucous membrane pemphigoid: Report of a case and review of literature.J Pharm Bioallied Sci. 2014 Apr;6(2):122-6. doi: 10.4103/0975-7406.129177. J Pharm Bioallied Sci. 2014. PMID: 24741281 Free PMC article.
-
HIV patient with mucous membrane pemphigoid: a case report.Ethiop J Health Sci. 2014 Apr;24(2):179-82. doi: 10.4314/ejhs.v24i2.12. Ethiop J Health Sci. 2014. PMID: 24795521 Free PMC article.
-
Management of a Large Palatal Ulcer: Mucous Membrane Pemphigoid.Cureus. 2023 Feb 28;15(2):e35619. doi: 10.7759/cureus.35619. eCollection 2023 Feb. Cureus. 2023. PMID: 37007312 Free PMC article.
-
Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin.Clin Exp Immunol. 2002 Sep;129(3):533-40. doi: 10.1046/j.1365-2249.2002.01942.x. Clin Exp Immunol. 2002. PMID: 12197896 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical